Case Studies

Ph1 trial of first-in-class drug through identification of new biology; better understanding MoA, biomarker ID and optimized indication selection.

OKN3201, potential first-in-class bispecific ADC for solid tumors.

A novel KRAS combination therapy for KRAS G12D-mutant PDAC patients.

Owkin transformed siloed, unstructured clinical data into a queryable patient registry.

Converse directly with histological data.

Owkin’s reports identify better patient subgroup biomarkers.